NASD · Healthcare · Medical Devices · United Kingdom
LivaNova PLC is a mid cap company (market value between $2 billion and $10 billion) in the Medical Devices industry.
LivaNova PLC designs, develops, and sells medical devices through two segments: Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides heart-lung machines, oxygenators, and related equipment for cardiac surgery. The Neuromodulation segment offers implantable devices for treating drug-resistant epilepsy and treatment-resistant depression, plus systems in development for obstructive sleep apnea. The company distributes globally to hospitals and healthcare professionals.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the LivaNova PLC stock.
Overvalued: intrinsic value $57.28 per share, market price $78.14, margin of safety -36.4% (as of 2026-10-19).
Discounting its cash flows at 9.3% (average of 3 methods) values the shares at $57.28; the price of $78.14 is 36% above that value, and 75% of that value comes from beyond year five.
Leak Score: 43/100 on 11 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
24 more in this industry show a wider margin of safety.
LIVN is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 9.3% (average of 3 methods) values the shares at $57.28; the price of $78.14 is 36% above that value, and 75% of that value comes from beyond year five.
$57.28 per share (as of the 2026-10-19 close), against a market price of $78.14. That is a margin of safety of -36.4%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
43 out of 100, which we rate "On Watch", on 11 of 12 value investing signals.